Cargando…

Low-dose anti-IL 5 treatment in idiopathic hypereosinophilic syndrome: towards a precision medicine approach for remission maintenance

Mepolizumab at the dose of 300 mg/4 weeks has been recently approved as an add-on therapy for patients with uncontrolled hypereosinophilic syndrome (HES) without any identifiable non-hematologic secondary cause. According to the available real-life evidence mepolizumab 300 mg and 100 mg, licensed fo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Caminati, Marco, Maule, Matteo, Benoni, Roberto, Micheletto, Claudio, Tecchio, Cristina, Vaia, Rachele, De Franceschi, Lucia, Guarnieri, Gabriella, Vianello, Andrea, Senna, Gianenrico
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10521477/ https://www.ncbi.nlm.nih.gov/pubmed/37752586 http://dx.doi.org/10.1186/s13023-023-02918-9

Ejemplares similares

Hidden Comorbidities in Asthma: A Perspective for a Personalized Approach
por: Maule, Matteo, et al.
Publicado: (2023)

Relevance of Smoking Habit in Severe Asthma Patients: Evidence from the Severe Asthma Network in Italy (SANI) Registry
por: Caminati, Marco, et al.
Publicado: (2022)

Severe Asthma, Telemedicine, and Self-Administered Therapy: Listening First to the Patient
por: Guarnieri, Gabriella, et al.
Publicado: (2022)

Uncontrolled Asthma: Unmet Needs in the Management of Patients
por: Caminati, Marco, et al.
Publicado: (2021)

Benralizumab Efficacy in Late Non-Responders to Mepolizumab and Variables Associated with Occurrence of Switching: A Real-Word Perspective
por: Caminati, Marco, et al.
Publicado: (2023)

New horizons for the treatment of severe, eosinophilic asthma: benralizumab, a novel precision biologic
por: Caminati, Marco, et al.
Publicado: (2019)

Who Is Really at Risk for Anaphylaxis Due to COVID-19 Vaccine?
por: Caminati, Marco, et al.
Publicado: (2021)

Diagnosis and Management of Allergic Rhinitis in Asthmatic Children
por: Tenero, Laura, et al.
Publicado: (2023)

Relative Humidity and Its Impact on the Immune System and Infections
por: Guarnieri, Gabriella, et al.
Publicado: (2023)

COVID-19 Vaccination in Patients with Severe Asthma on Biologic Treatment: Safety, Tolerability, and Impact on Disease Control
por: Caminati, Marco, et al.
Publicado: (2021)

Clinical response to biologicals for severe asthma: any relevance for sex in different age ranges?
por: Benoni, Roberto, et al.
Publicado: (2022)

Correlation between α1-Antitrypsin Deficiency and SARS-CoV-2 Infection: Epidemiological Data and Pathogenetic Hypotheses
por: Vianello, Andrea, et al.
Publicado: (2021)

Idiopathic hypereosinophilic syndrome in remission with benralizumab treatment after relapse with mepolizumab
por: Fujii, Koki, et al.
Publicado: (2020)

Low adherence to inhaled corticosteroids/long-acting β(2)-agonists and biologic treatment in severe asthmatics
por: Caminati, Marco, et al.
Publicado: (2020)

Relationship between hair shedding and systemic inflammation in COVID-19 pneumonia
por: Guarnieri, Gabriella, et al.
Publicado: (2022)

Organization, Clinical and Management Indicators on the First Year of Activity of an Outpatient Clinic Dedicated to the Diagnosis and Treatment of Severe Asthma in Italy
por: Tognella, Silvia, et al.
Publicado: (2021)

Asthma in a large COVID-19 cohort: Prevalence, features, and determinants of COVID-19 disease severity
por: Caminati, Marco, et al.
Publicado: (2021)

Asthmatic patients in COVID-19 outbreak: Few cases despite many cases
por: Caminati, Marco, et al.
Publicado: (2020)

Response to a case report: Idiopathic hypereosinophilic syndrome in remission with benralizumab treatment after relapse with mepolizumab
por: Requena, Gema, et al.
Publicado: (2021)

Idiopathic hypereosinophilic syndrome with pulmonary hypertension
por: Zhang, Liping, et al.
Publicado: (2018)

Idiopathic hypereosinophilic syndrome presenting with liver mass: Report of two cases: Idiopathic hypereosinophilic syndrome and liver mass
por: shatery, Kamran, et al.
Publicado: (2011)

Targeting eosinophils: severe asthma and beyond
por: Caminati, Marco, et al.
Publicado: (2019)

The potential protective role of corticosteroid therapy in patients with asthma and COPD against COVID-19
por: Furci, Fabiana, et al.
Publicado: (2021)

TSLP and HMGB1: Inflammatory Targets and Potential Biomarkers for Precision Medicine in Asthma and COPD
por: Furci, Fabiana, et al.
Publicado: (2023)

Idiopathic Hypereosinophilic Syndrome with Multiple Organ Involvement
por: Abo Shdid, Reham, et al.
Publicado: (2021)

Idiopathic Hypereosinophilic Syndrome Presenting With Embolic Stroke
por: Silva, Magda S, et al.
Publicado: (2021)

Idiopathic Hypereosinophilic Syndrome: A Case Report
por: Agudo, Margarida, et al.
Publicado: (2023)

Reply to Correspondence: Response to a case report: idiopathic hypereosinophilic syndrome in remission with benralizumab treatment after relapse with mepolizumab
por: Fujii, Koki, et al.
Publicado: (2021)

IL-33 and the Cytokine Storm in COVID-19: From a Potential Immunological Relationship towards Precision Medicine
por: Furci, Fabiana, et al.
Publicado: (2022)

Drop-out rate among patients treated with omalizumab for severe asthma: Literature review and real-life experience
por: Caminati, M., et al.
Publicado: (2016)

Dysphonia and dyspnea in idiopathic hypereosinophilic syndrome treated with Mepolizumab
por: Kay, Dana, et al.
Publicado: (2018)

Idiopathic hypereosinophilic syndrome with 20 years of diagnostic delay
por: Neto, Miguel Pedro de Queiroz, et al.
Publicado: (2017)

Idiopathic hypereosinophilic syndrome: A rare diagnosis in children
por: Pallesen, Kristine Appel Uldall, et al.
Publicado: (2020)

Idiopathic hypereosinophilic syndrome with cutaneous necrosis and multiorgan embolism
por: Wang, Huan, et al.
Publicado: (2019)

Idiopathic hypereosinophilic syndrome in hemodialysis patients: Case reports
por: Mutsuyoshi, Yuko, et al.
Publicado: (2021)

Upsides and downsides of a telecounselling model of integrated asthma management between general practitioners and specialists
por: Furci, Fabiana, et al.
Publicado: (2022)

The intriguing possibility of using probiotics in allergen-specific immunotherapy
por: Furci, Fabiana, et al.
Publicado: (2023)

Fatal Outcome of Imatinib in a Patient with Idiopathic Hypereosinophilic Syndrome
por: Abugroun, Ashraf, et al.
Publicado: (2018)

Idiopathic Hypereosinophilic Syndrome in an Elderly Female: A Case Report
por: Khalid, Faiza, et al.
Publicado: (2019)

Skin-limited idiopathic hypereosinophilic syndrome presenting with retiform purpura
por: Yu, Zizi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_r1vct1tj0obhb4r10uob20si2m